Abnormal Thyroid Levels in Leukemia: What They Mean and When to Worry

Abnormal thyroid tests are relatively common during leukemia diagnosis and treatment, and they often reflect temporary changes rather than permanent thyroid disease. In many cases, thyroid abnormalities during chemotherapy especially in children represent “non‑thyroidal illness syndrome” (NTIS), which usually resolves without specific thyroid medication. [PM14] After hematopoietic stem cell transplantation (HSCT), clinically significant hypothyroidism is more frequent, particularly when total‑body irradiation (TBI) was part of conditioning, and it may require long‑term follow‑up and treatment. [PM20] When true hypothyroidism is confirmed, levothyroxine replacement is typically effective, and therapy adequacy is monitored with TSH and/or T4 testing. ^[1]

---

Why Thyroid Tests Can Be Abnormal During Leukemia Care

• Non‑thyroidal illness syndrome (NTIS): Serious illness and inflammation can temporarily lower T3/FT3 and sometimes FT4, with normal or low‑normal TSH, without true thyroid failure. In newly diagnosed pediatric ALL, NTIS prevalence increased from about 45% before induction chemotherapy to over 70% after induction, largely driven by inflammation and treatment effects, and most cases normalized without hormones. [PM14]

• Treatment effects and long‑term changes: Some therapies, especially HSCT with TBI, can injure thyroid tissue, leading to persistent hypothyroidism months to years later. In long‑term pediatric HSCT survivors, hypothyroidism occurred in roughly one‑third, with TBI being the strongest risk factor. [PM20] Endocrine complications, including hypothyroidism, are recognized late effects in HSCT cohorts. [PM19]

• Immunotherapy‑related thyroiditis (if applicable): Immune checkpoint inhibitors can trigger painless thyroiditis, transient hyperthyroidism, and then hypothyroidism; overt hypothyroidism is treated with levothyroxine and thyroid function is monitored every 4–6 weeks during therapy. ^{[2] [3]}

---

What This Means for Prognosis and Safety

• Often temporary during chemotherapy: NTIS generally does not signal worsening leukemia or poor short‑term treatment outcome and tends to improve as inflammation settles. [PM14]
• Important survivorship issue after HSCT/TBI: Persistent hypothyroidism can affect energy, growth (in children), and metabolic health if untreated, so routine screening and timely thyroid hormone replacement are important for long‑term quality of life. [PM20] [PM19]
• Manageable when true hypothyroidism is present: Levothyroxine safely restores normal levels; doctors check TSH and/or T4 periodically to ensure the dose is right. ^[1]

---

How Doctors Evaluate Abnormal Thyroid Results

• Pattern matters: In NTIS, T3/FT3 is low with normal or mildly abnormal TSH, often without symptoms; clinicians typically monitor rather than treat. [PM14]
• Confirming hypothyroidism: Elevated TSH with low FT4 suggests true hypothyroidism and usually warrants levothyroxine. Dose adequacy is assessed by periodic lab tests and clinical review. ^[1]
• Post‑HSCT surveillance: Regular thyroid function testing is part of survivorship care, especially after TBI, because late hypothyroidism is common. [PM20] [PM19]
• If on immunotherapy: TSH and FT4 are checked every 4–6 weeks; symptoms guide additional tests and management. ^[3]

---

When to Be Concerned

Consider reaching out to your care team if you notice:

• Persistent fatigue, cold intolerance, weight gain, constipation, dry skin, or slowed thinking, which may suggest hypothyroidism and merit evaluation and possible treatment. When hypothyroidism is confirmed, levothyroxine is started and monitored. ^[1]
• Palpitations, heat intolerance, anxiety, tremor, or unexplained weight loss, which can signal hyperthyroidism; beta‑blockers can help symptoms, and further evaluation is done to confirm the cause. ^[4]
• History of HSCT or prior TBI, because the risk of lasting hypothyroidism is higher and routine screening is recommended. [PM20] [PM19]

---

Practical Tips During Leukemia Treatment

• Ask which pattern your labs show (NTIS vs true hypothyroidism/hyperthyroidism) and whether treatment is needed now or just monitoring. Most chemotherapy‑related NTIS cases normalize without thyroid hormone therapy. [PM14]
• Keep a symptom diary and share changes with your team; symptoms guide whether to adjust monitoring or start treatment. Therapy adequacy is measured by TSH/T4 trends and how you feel. ^[1]
• After HSCT, plan routine endocrine follow‑up, including thyroid testing, to catch late effects early. Long‑term monitoring improves quality of life by enabling timely treatment of hypothyroidism and other endocrine issues. [PM20] [PM19]

---

Summary

Abnormal thyroid levels during leukemia care are common and often temporary, especially during chemotherapy where NTIS predominates and usually resolves without treatment. [PM14] After HSCT, particularly with TBI, long‑term hypothyroidism is more frequent and should be screened for and treated. [PM20] When true hypothyroidism is present, levothyroxine is effective, with regular checks of TSH and/or T4 to fine‑tune dosing. ^[1] With appropriate monitoring, most thyroid issues can be managed safely without worsening leukemia outcomes. [PM14] [PM20]

---

궁금한 점 있으면 언제든 퍼슬리에 물어보세요.